Vet drug monepantel slows ALS, MND disease progression in trial
Daily treatment with monepantel — a drug widely used in veterinary medicine — was shown to reduce the rate…
Articles by Andrea Lobo, PhD
PrimeC in ALS patients shown to extend complication-free survival
Treatment with NeuroSense Therapeutics’ PrimeC was found to extend patients’ time without complications or death, and to lead to…
OrphAI’s AIT-101 granted orphan drug status in Europe for ALS
OrphAI Therapeutics’ experimental therapy AIT-101 has been awarded orphan drug status in the European Union for amyotrophic lateral…
Committee favors EU approval of Qalsody for adults with SOD1-ALS
An advisory committee of the European Medicines Agency (EMA) has recommended that Biogen’s Qalsody (tofersen) be approved in the…
Phase 1 trial testing prosetin for ALS expands to EU countries
ProJenX has been given the green light to expand its ongoing Phase 1 clinical trial of prosetin for amyotrophic…
TPN-101 improves ALS/FTD caused by C9orf72 gene mutations
TPN-101, an investigational oral molecule developed by Transposon Therapeutics, reduced multiple biomarkers of neuroinflammation and neurodegeneration, and slowed respiratory…
$400K ALS Association grant will advance CSF-1R inhibitor program
Myrobalan Therapeutics will use a $400,000 grant from the ALS Association — along with $24 million in new…
$20K gift supports Ball State work into C9orf72-linked ALS
A research team at Ball State University has received a $20,000 donation from the Todd Siebert Memorial Foundation…
Phase 2 trial of oral IFB-088 for bulbar-onset ALS now fully enrolled
Enrollment is complete in a Phase 2 trial testing InFlectis BioScience’s oral candidate IFB-088 (icerguastat) in people with…
Trial of cell-based therapy CK08031 finishes dosing 1st patient group
An early-stage clinical trial evaluating CK0803, Cellenkos‘ regulatory T-cell-based therapy for people with amyotrophic lateral sclerosis (ALS), has…